148 related articles for article (PubMed ID: 37843260)
21. Relationship between Pharmacokinetic/Pharmacodynamic Target Attainment and Microbiological Outcome in Critically Ill COVID-19 Patients with Documented Gram-Negative Superinfections Treated with TDM-Guided Continuous-Infusion Meropenem.
Sanz Codina M; Gatti M; Troisi C; Fornaro G; Pasquini Z; Trapani F; Zanoni A; Caramelli F; Viale P; Pea F
Pharmaceutics; 2022 Jul; 14(8):. PubMed ID: 36015211
[TBL] [Abstract][Full Text] [Related]
22. Continuous infusion, therapeutic drug monitoring and outpatient parenteral antimicrobial therapy with ceftazidime/avibactam: a retrospective cohort study.
Goncette V; Layios N; Descy J; Frippiat F
J Glob Antimicrob Resist; 2021 Sep; 26():15-19. PubMed ID: 33989847
[TBL] [Abstract][Full Text] [Related]
23. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
Sharma R; Park TE; Moy S
Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
[TBL] [Abstract][Full Text] [Related]
24. Population Pharmacokinetic Modeling and Probability of Pharmacodynamic Target Attainment for Ceftazidime-Avibactam in Pediatric Patients Aged 3 Months and Older.
Franzese RC; McFadyen L; Watson KJ; Riccobene T; Carrothers TJ; Vourvahis M; Chan PLS; Raber S; Bradley JS; Lovern M
Clin Pharmacol Ther; 2022 Mar; 111(3):635-645. PubMed ID: 34687548
[TBL] [Abstract][Full Text] [Related]
25. Steady-State Ceftazidime-Avibactam Serum Concentrations and Dosing Recommendations in a Critically Ill Patient Being Treated for Pseudomonas aeruginosa Pneumonia and Undergoing Continuous Venovenous Hemodiafiltration.
Soukup P; Faust AC; Edpuganti V; Putnam WC; McKinnell JA
Pharmacotherapy; 2019 Dec; 39(12):1216-1222. PubMed ID: 31596506
[TBL] [Abstract][Full Text] [Related]
26. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.
Zhanel GG; Lawson CD; Adam H; Schweizer F; Zelenitsky S; Lagacé-Wiens PR; Denisuik A; Rubinstein E; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2013 Feb; 73(2):159-77. PubMed ID: 23371303
[TBL] [Abstract][Full Text] [Related]
27. The pharmacokinetics/pharmacodynamics of ceftazidime/avibactam for central nervous system infections caused by carbapenem-resistant Gram-negatives: a prospective study.
Xu Y; Luo X; Yuan B; Liang P; Liu N; Dong D; Ge W; Gu Q
J Antimicrob Chemother; 2024 Apr; 79(4):820-825. PubMed ID: 38366379
[TBL] [Abstract][Full Text] [Related]
28. A novel mechanism-based pharmacokinetic-pharmacodynamic (PKPD) model describing ceftazidime/avibactam efficacy against β-lactamase-producing Gram-negative bacteria.
Kristoffersson AN; Bissantz C; Okujava R; Haldimann A; Walter I; Shi T; Zampaloni C; Nielsen EI
J Antimicrob Chemother; 2020 Feb; 75(2):400-408. PubMed ID: 31670804
[TBL] [Abstract][Full Text] [Related]
29. The primary pharmacology of ceftazidime/avibactam: in vivo translational biology and pharmacokinetics/pharmacodynamics (PK/PD).
Nichols WW; Bradford PA; Stone GG
J Antimicrob Chemother; 2022 Aug; 77(9):2341-2352. PubMed ID: 35660869
[TBL] [Abstract][Full Text] [Related]
30. Multicentre study of ceftazidime/avibactam for Gram-negative bacteria infections in critically ill patients.
Balandín B; Ballesteros D; Pintado V; Soriano-Cuesta C; Cid-Tovar I; Sancho-González M; Pérez-Pedrero MJ; Chicot M; Asensio-Martín MJ; Silva JA; de Luna RR; Gesso CM; Rodríguez-Serrano DA; Martínez-Sagasti F; Royuela A
Int J Antimicrob Agents; 2022 Mar; 59(3):106536. PubMed ID: 35091054
[TBL] [Abstract][Full Text] [Related]
31. Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae.
Santevecchi BA; Smith TT; MacVane SH
Int J Antimicrob Agents; 2018 Apr; 51(4):629-635. PubMed ID: 29408227
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of ceftazidime/avibactam in monotherapy or combination therapy against carbapenem-resistant Gram-negative bacteria: A meta-analysis.
Onorato L; Di Caprio G; Signoriello S; Coppola N
Int J Antimicrob Agents; 2019 Dec; 54(6):735-740. PubMed ID: 31479738
[TBL] [Abstract][Full Text] [Related]
33. Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012).
Flamm RK; Farrell DJ; Sader HS; Jones RN
J Antimicrob Chemother; 2014 Jun; 69(6):1589-98. PubMed ID: 24562613
[TBL] [Abstract][Full Text] [Related]
34.
Stone GG; Bradford PA; Tawadrous M; Taylor D; Cadatal MJ; Chen Z; Chow JW
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32071051
[TBL] [Abstract][Full Text] [Related]
35. Relationship Between Real-time TDM-guided Pharmacodynamic Target Attainment of Continuous Infusion Beta-lactam Monotherapy and Microbiologic Outcome in the Treatment of Critically Ill Children With Severe Documented Gram-negative Infections.
Gatti M; Campoli C; Latrofa ME; Ramirez S; Sasso T; Mancini R; Caramelli F; Viale P; Pea F
Pediatr Infect Dis J; 2023 Nov; 42(11):975-982. PubMed ID: 37523585
[TBL] [Abstract][Full Text] [Related]
36. The primary pharmacology of ceftazidime/avibactam: microbiology from clinical studies, and development of resistance during treatment.
Nichols WW; Bradford PA; Stone GG
J Antimicrob Chemother; 2023 Apr; 78(4):871-892. PubMed ID: 36883356
[TBL] [Abstract][Full Text] [Related]
37. Microbiological interaction studies between ceftazidime-avibactam and pulmonary surfactant and between ceftazidime-avibactam and antibacterial agents of other classes.
Dallow J; Otterson LG; Huband MD; Krause KM; Nichols WW
Int J Antimicrob Agents; 2014 Dec; 44(6):552-6. PubMed ID: 25293578
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis.
Bensman TJ; Wang J; Jayne J; Fukushima L; Rao AP; D'Argenio DZ; Beringer PM
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784670
[TBL] [Abstract][Full Text] [Related]
39. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.
Carmeli Y; Armstrong J; Laud PJ; Newell P; Stone G; Wardman A; Gasink LB
Lancet Infect Dis; 2016 Jun; 16(6):661-673. PubMed ID: 27107460
[TBL] [Abstract][Full Text] [Related]
40. Ceftazidime-avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections.
Mawal Y; Critchley IA; Riccobene TA; Talley AK
Expert Rev Clin Pharmacol; 2015; 8(6):691-707. PubMed ID: 26420166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]